Study Finds Elevated Birth Defect Risk with ICSI, Reinforcing Importance of Informed Counselling
A large South Australian registry analysis found that birth-defect risk associated with IVF was no longer significant after adjustment, while risk associated with intracytoplasmic sperm injection remained elevated. Intracytoplasmic sperm injection (ICSI), once viewed as a breakthrough for severe male-factor infertility, may carry a higher observed risk of birth defects than conventional in vitro fertilization (IVF), according to a registry-based study published in the New England Journal of Medicine.
The study, led by Michael J. Davies and colleagues, linked assisted reproductive technology treatment records in South Australia with birth, termination, and birth-defect registries. Investigators reviewed 308,974 births, including 6,163 births following assisted conception, and assessed birth defects diagnosed before a child’s fifth birthday.
Overall, birth defects were recorded in 8.3% of pregnancies involving assisted conception compared with 5.8% of pregnancies not involving assisted conception. After adjustment for factors such as maternal demographics, medical conditions, and pregnancy complications, assisted conception remained associated with a modestly increased risk.
When IVF and ICSI were analysed separately, the adjusted association differed by procedure. For conventional IVF, the increased risk was no longer statistically significant after adjustment. For ICSI, however, the association persisted: birth defects were reported in 9.9% of ICSI pregnancies, and the adjusted odds ratio was 1.57 compared with unassisted conception.
The authors cautioned that residual confounding could not be excluded. In practical terms, the study cannot prove that ICSI itself causes birth defects. The signal may reflect factors linked to infertility, particularly severe male-factor infertility, or other unmeasured parental and treatment-related variables.
ICSI involves injecting a selected sperm cell directly into a mature oocyte. Since its introduction in the early 1990s, it has transformed care for men with very low sperm counts, poor motility, abnormal sperm morphology, obstructive azoospermia, and non-obstructive azoospermia where sperm can be retrieved from the testis or epididymis.
Over time, ICSI has also been used beyond classic male-factor infertility, including after failed IVF cycles, in mixed-factor infertility, and sometimes as a precautionary “safety-net” during IVF. The evidence supporting these broader indications remains less certain.
Researchers have raised several theoretical and clinical concerns about ICSI-conceived offspring. These include the possible transmission of paternal chromosomal abnormalities, Y-chromosome microdeletions, sperm DNA damage, imprinting disorders, congenital malformations, and long-term developmental outcomes.
Because ICSI bypasses several natural barriers to fertilization, sperm selection is usually based on appearance and motility rather than direct confirmation of chromosomal or DNA integrity. This has prompted calls for more rigorous assessment of male infertility and better integration of sperm DNA-fragmentation testing where clinically appropriate.
The findings do not mean that ICSI should be avoided when clearly indicated. For many couples with severe male-factor infertility, ICSI remains an essential treatment option. However, the data support more careful patient selection and counselling, particularly when ICSI is proposed without a strong sperm-related indication.
Clinicians should discuss both the absolute and relative risks with patients. Although the study reported a higher percentage of birth defects after ICSI than after IVF, most children conceived through assisted reproduction are born without major congenital abnormalities.
The South Australian analysis included treatment data from 1986 to 2002, and assisted reproduction techniques have evolved substantially since then. The study also could not fully separate the effect of the procedure from the effect of underlying infertility, paternal factors, embryo-transfer practices, multiple pregnancy, or differences in how birth defects were classified.
Other studies and meta-analyses have reported smaller differences between IVF and ICSI, and some more recent cohorts have not found a statistically significant increase in congenital malformations with ICSI compared with conventional IVF. These differences underline the need for consistent definitions, long-term follow-up, and modern registry data.
The report reinforces the need for a complete infertility work-up, including appropriate male-factor evaluation, before moving directly to ICSI. It also supports transparent counselling about uncertainties, potential risks, and alternative treatment strategies where suitable.
Experts continue to call for surveillance of children born after ICSI and other assisted reproductive technologies. Future research should distinguish procedural risk from parental infertility risk and should account for modern laboratory methods, single-embryo transfer practices, and improved prenatal and paediatric monitoring.
Source: Hindawi Publishing Corporation Obstetrics and Gynecology International
Volume2013,ArticleID473289
http://dx.doi.org/10.1155/2013/473289
